Pierrel Valuation
Is 0FP4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0FP4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0FP4's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0FP4's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0FP4?
Key metric: As 0FP4 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0FP4's PE Ratio? | |
|---|---|
| PE Ratio | 30.8x |
| Earnings | €3.11m |
| Market Cap | €95.58m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 23x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 0FP4's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.5x | ||
ANCR Animalcare Group | 32.1x | 15.8% | UK£148.5m |
EAH ECO Animal Health Group | 42.3x | 34.2% | UK£44.4m |
HIK Hikma Pharmaceuticals | 19.2x | 12.7% | UK£4.4b |
BVXP Bioventix | 24.2x | n/a | UK£195.7m |
0FP4 Pierrel | 30.8x | n/a | €95.6m |
Price-To-Earnings vs Peers: 0FP4 is good value based on its Price-To-Earnings Ratio (30.8x) compared to the peer average (49.1x).
Price to Earnings Ratio vs Industry
How does 0FP4's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0FP4 is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the European Pharmaceuticals industry average (21.8x).
Price to Earnings Ratio vs Fair Ratio
What is 0FP4's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0FP4's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.80
7D
1.9%
1Y
12.1%
hVIVO
UK£134.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.20
7D
-16.8%
1Y
2.1%
Regeneron Pharmaceuticals
US$80.6b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$750.19
7D
0.5%
1Y
-5.7%